Huadong Medicine Group
Guided by the philosophy of “research-driven and patient-centered,” we are committed to becoming a leading international pharmaceutical brand powered by scientific and technological innovation.
Huadong Medicine Co., Ltd. is headquartered in Hangzhou, Zhejiang Province. Huadong Medicine has been repeatedly recognized among the “Top 50 Best Listed Companies in Asia-Pacific” by Forbes, ranked among the “Top 100 Most Valuable Listed Companies in China’s Main Board Market”, and has been included for many consecutive years in the Fortune China 500 list selected by Fortune China. It was also selected among the Top 50 Global Pharmaceutical Companies in 2025 by the U.S. magazine Pharmaceutical Executive. It has also been ranked among the Top 10 in the “China Top 100 Pharmaceutical Industrial Enterprises” for consecutive years. With a business presence spanning the entire pharmaceutical industry chain, Huadong Medicine operates across four business segments, including pharmaceutical manufacturing, pharmaceutical distribution, medical aesthetics, and industrial microbiology, and has grown into a large, comprehensive listed pharmaceutical company integrating pharmaceutical innovative R&D, manufacturing, and commercialization.
The company spans the entire pharmaceutical industry chain, focusing on four core segments: pharmaceutical development, pharmaceutical distribution, medical aesthetics, and microbiology. Today, it stands as a leading pharmaceutical enterprise specializing in innovative R&D, manufacturing, sales, and marketing.
Huadong Medicine has long been engaged in the R&D, manufacturing, and commercialization of specialty therapies, chronic disease medicines, and special-use medicines. With a complete, internationally oriented pharmaceutical manufacturing system, it has formed core product pipelines mainly covering chronic kidney disease, immunology, oncology, endocrinology, and digestive system diseases. Huadong Medicine has multiple frontline clinical products with strong market positions in China, and many products have obtained international registration certifications. It maintains R&D collaborations with a number of global innovation-driven R&D companies and has established China-market product strategic partnerships with multinational pharmaceutical companies, building the Huadong Medicine global R&D ecosystem. Through in-house development, external introductions, and project collaborations, it has focused its R&D on three core therapeutic areas: oncology, endocrinology, and autoimmune diseases. Leveraging its full industry chain to support biopharmaceutical industrialization, Huadong Medicine has invested in and built an internationally leading biomacromolecular drug R&D platform—the Biologics Innovation & Intelligent Manufacturing Center. The platform is dedicated to creating an end-to-end intelligent manufacturing base for biologics, focusing on high-barrier therapies such as monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs. Backed by an intelligent manufacturing ecosystem and globally compliant production capacity, it accelerates the efficient translation of First-in-Class molecules from the laboratory to global markets, completing a closed-loop innovation chain across the full biologics value chain and advancing breakthrough therapies to benefit patients worldwide.
Oncology
We are committed to building a world-leading platform for innovative oncology drug R&D. It has established an oncology pipeline spanning targeted small-molecule drugs, ADCs, antibodies, PROTACs and other modalities, with more than a dozen globally innovative drug programs. In the oncology ADC field in particular, Huadong Medicine partnered with ImmunoGen (U.S.) to develop ELAHERE®, a first-in-class ADC for platinum-resistant ovarian cancer, which has been approved and launched in China. Meanwhile, it has successively invested in, acquired/controlled, and incubated multiple biotech companies in China with leading technologies, building a complete ADC technology ecosystem covering antibody discovery, linker technologies, and payload development. Huadong Medicine also operates an ADC R&D platform in Heidelberg, Germany—its European ADC drug development center—featuring a proprietary antibody technology platform (the amanitin platform). This is currently the only platform that has advanced amanitin-based ADCs into the clinical stage. Its HDP101 program for multiple myeloma has received U.S. FDA Fast Track designation, and HDP103 is an amanitin-based ADC targeting PSMA for prostate cancer, currently at the IND submission stage. Leveraging its unique global ADC R&D ecosystem, Huadong Medicine will continue to develop differentiated, innovative ADC therapies. As one of the earlier companies in China to enter the CAR-T space, Huadong Medicine has partnered with advanced domestic biopharmaceutical companies. Its product Saikaize® (Zevorcabtagene Autoleucel Injection) has become one of China’s leading cell therapies for multiple myeloma. In addition, an autologous CD19-targeted CAR-T candidate for diffuse large B-cell lymphoma, mantle cell lymphoma, and acute B lymphoblastic leukemia had its NDA accepted for review in November 2024. Through deep strategic deployment in CAR-T, Huadong Medicine will continue to strengthen its competitiveness in the oncology market going forward.
Endocrinology
We have established a comprehensive portfolio of innovative drugs and differentiated generics covering the major clinical therapeutic targets for diabetes, with more than 20 products either commercialized or under development. In particular, focusing on the GLP-1 target, Huadong Medicine has built a diversified and all-around product pipeline that integrates global innovative drugs and biosimilars, covering multiple dosage forms such as oral and injectable formulations, as well as long-acting and multi-target therapies. Liraglutide injection has obtained NMPA approval in China for both diabetes and obesity/overweight indications, making it the first domestically developed product approved for these indications. In addition, DR10624, a globally first-in-class long-acting triple agonist independently developed by the company’s controlled subsidiary, is currently undergoing multiple cutting-edge clinical studies. Clinical results have demonstrated that DR10624 delivers significant efficacy in reducing triglyceride levels, comprehensively improving lipid profiles, rapidly and significantly eliminating hepatic fat, enhancing insulin sensitivity, and lowering uric acid levels. At the 2025 American Heart Association (AHA) Scientific Sessions, this study was presented as a breakthrough opening-session report on the main stage and was recognized as a pioneering clinical trial in cardiometabolic disease therapeutics, attracting significant attention and highly positive evaluations from experts across the field.
Autoimmunity
Huadong Medicine has become one of the most comprehensive pharmaceutical companies in China in the field of autoimmune diseases, with a pipeline of more than 20 innovative biologics and small-molecule drugs currently under development. At the same time, the company has expanded into topical formulations by establishing a dedicated R&D platform for these products, which covers a wide range of indications. Huadong Medicine has developed and commercialized 10 topical products, leveraging a fully integrated system for R&D, registration, production, and commercialization. Notably, the company has introduced two global firsts through partnerships: Wynzora® Cream, the world’s first and only once-daily combination of calcipotriene and betamethasone dipropionate in a water-based cream for the treatment of plaque psoriasis, and ZORYVE® Cream, the first and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis (including intertriginous psoriasis).
As a leading regional pharmaceutical distributor, Huadong Medicine has ranked among China’s top 10 pharmaceutical wholesalers for many consecutive years. Covering three major business segments—pharmaceuticals, medical devices, and herbal decoction pieces—the company is anchored by a smart logistics network with three core hubs in Hangzhou, Jinhua, and Wenzhou, supported by 13 logistics and warehousing facilities with a total storage area exceeding 190,000 square meters. Competitiveness is further strengthened through specialized logistics services for cold-chain products, specialty drugs, and vaccines. The pharmaceutical segment offers comprehensive advantages across the full product portfolio and all distribution channels, enabling seamless linkage between in-hospital and out-of-hospital supply as well as coordinated distribution and agency services, and has established business partnerships with over 95% of the world’s top 50 pharmaceutical companies and China’s top 100 pharmaceutical enterprises. The medical device segment expands specialized agency services by leveraging large-scale distribution capabilities. The herbal medicine, ginseng & antler, and decoction pieces segment spans the entire value chain—from base-level cultivation and decoction piece processing to automated decoction services and the sales of proprietary branded functional products.
The wholly owned subsidiary, Sinclair, with nearly 50 years of scientific heritage, serves as a global operating platform in the medical aesthetics field. Centered on a Full-Spectrum Health Aesthetics strategy and driven by technology and innovation, Sinclair has built a full-spectrum health aesthetics product portfolio, comprising more than 40 internationally positioned, high-end medical aesthetics products, including injectable products as well as energy-based devices (EBD). In terms of both product breadth and application coverage, the portfolio ranks among the industry leaders. Ellanse® is the first imported regenerative dermal filler approved in China. Lanluma® is the world’s only regenerative injectable aesthetic product approved for body contouring and was awarded the “Best Body Filler Injection Award” at the 2023 Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco. KIO021, a globally pioneering non-animal-derived chitosan aesthetic filler, is the world’s only medical-grade, high-purity natural chitosan extracted from edible fungi, representing a breakthrough in regenerative medical aesthetics. We operate global R&D and manufacturing centers across the United Kingdom, France, the Netherlands, Switzerland, Belgium, Spain, Bulgaria, and Israel. Supported by strong technological capabilities and real-time global industry insights, Sinclair has established mature sales and marketing networks in North America, the European Union, Brazil, Mexico, the United Arab Emirates, Hong Kong (China), and South Korea. Leveraging its global operating platform, Sinclair’s commercial reach extends to more than 80 countries and regions worldwide.
Huadong Medicine has a solid industrial foundation and strong industrialization capability in industrial microbiology, successfully developing and manufacturing multiple microbial-based pharmaceuticals, and establishing a complete technology system for microbial product R&D and production. Our current fermentation production capacity and technological sophistication rank among the industry leaders. We focus on two strategic directions—synthetic biology innovation and biopharmaceutical industry upgrading—advancing core business segments including xRNA, specialty APIs & intermediates, wellness & biomaterials, and animal health.
The industrial microbiology R&D platform is centered on Huadong Industrial Microbiology R&D operations in China and the United States, and is jointly supported by an integrated R&D matrix including the Synthetic Biology Industrial Technology Research Institute, Huida Biotech, and bio-based materials research teams. The platform possesses full-chain microbial engineering capabilities and operates one of the largest single-unit fermentation workshop facilities in Zhejiang Province. Its microbial pharmaceutical manufacturing capacity ranks among the leading levels in the industry. An integrated R&D and production system covering the entire lifecycle of microbial pharmaceuticals has been established, together with a cross-disciplinary R&D platform and an industrialization resource network that supports efficient technology translation and scale-up.